Virpax Pharmaceuticals, Inc. 8-K Report: Key Insights & Market Updates

Based on the provided section of the financial report, here are the key insights and information extracted:

1. Company Identification:

• Name: Virpax Pharmaceuticals, Inc.
• CIK (Central Index Key): 0001708331
• SEC File Number: 001-40064
• EIN (Employer Identification Number): 82-1510982
• Address: 1055 Westlakes Drive, Suite 300, Berwyn, PA 19312
• Contact Number: (610) 727-4597

2. Report Type:

• Filing Type: 8-K (Current Report)

3. Reporting Date:

• As Of Date: December 17, 2024

4. Stock Information:

• Common Stock: The par value is $0.00001 per share.
• Ticker Symbol: VRPX
• Exchange: NASDAQ

5. Financial Units:

• Currency: USD (US Dollars)
• Shares: The report indicates a unit of measure for shares.

6. Context Information:

• The filing provides a context for the financial data as of the end date of December 17, 2024.

Insights:

• This filing represents an important regulatory disclosure for Virpax Pharmaceuticals, indicating potential significant events or changes relevant to shareholders and the market.
• The information can be critical for investors assessing the company's financial health, stock performance, and overall market position.
• The details suggest that the company is publicly traded and is required to file reports to keep investors informed about its operations and financial condition.

Overall, this section of the financial report is essential for stakeholders who need to understand Virpax Pharmaceuticals’ current status and market presence.